These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7169608)

  • 1. The metabolic fate of 11-bromo-[15-3H] vincamine in rats, dogs and humans.
    Mayo BC; Biggs SR; Hawkins DR; Chasseaud LF; Darragh A; Baldock GA; Whitby BR
    J Pharmacobiodyn; 1982 Dec; 5(12):951-64. PubMed ID: 7169608
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolism of vincamine in the rat in vivo and in vitro.
    Vereczkey L; Tamás J; Czira G; Szporny L
    Arzneimittelforschung; 1980; 30(11):1860-5. PubMed ID: 7192994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic fate of 11-bromo[15-3H]vincamine in man.
    Mayo BC; Biggs SR; Hawkins DR; Chasseaud LF; Darragh A; Leaf FC
    Eur J Drug Metab Pharmacokinet; 1985; 10(3):189-96. PubMed ID: 4085521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metabolism of vincamine in the rat].
    Viganò V; Paracchini S; Piacenza G; Pesce E
    Farmaco Sci; 1978 Aug; 33(8):583-94. PubMed ID: 744256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kinetic behavior of 3H-vincamine in man. Compartmental analysis].
    Camón L; Rodríguez Farré E; Valdecasas FG
    Arch Farmacol Toxicol; 1978 Apr; 4(1):39-40. PubMed ID: 697401
    [No Abstract]   [Full Text] [Related]  

  • 6. [Biopharmaceutics of vincamine salts after oral administration in humans].
    Aiache JM; Turlier M; Sibaud Y
    Farmaco Prat; 1985 Mar; 40(3):87-100. PubMed ID: 3996561
    [No Abstract]   [Full Text] [Related]  

  • 7. [Absorption, distribution and elimination of vincamine hydrochloride in the rat].
    Vigano V; Rognoni F; Piacenza G; Pesce E
    Farmaco Prat; 1978 May; 33(5):224-31. PubMed ID: 744225
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on the vincamine-papaverine association. i. biochemical investigations.
    Costrini R; Galzigna L; Bianchi M; Nunziata A; Cattani L
    Agressologie; 1978; 19(3):211-4. PubMed ID: 736220
    [No Abstract]   [Full Text] [Related]  

  • 9. [Autoradiographic demonstration of the passage of vincamin through the blood-brain barrier].
    Sprumont P; Lintermans J
    Fortschr Med; 1982 Mar; 100(11):471-5. PubMed ID: 7076076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of vincamine and related compounds.
    Vereczkey L
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):89-103. PubMed ID: 3899662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoradiographic evidence for passage of vincamine through the blood-brain barrier.
    Sprumont P; Lintermans J
    Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):42-8. PubMed ID: 485685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologic availability of vincamine from tablets with a hydrophilic matrix. II].
    Rolland A; Gibassier D; Chemtob C; Le Verge R
    J Pharm Belg; 1984; 39(3):136-44. PubMed ID: 6481608
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic study of vincamine teprosilate.
    Cadórniga R; Saiz Vadillo MC; Molina IT; Cadórniga L
    Int J Clin Pharmacol Res; 1984; 4(4):281-90. PubMed ID: 6500775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles.
    Maincent P; Le Verge R; Sado P; Couvreur P; Devissaguet JP
    J Pharm Sci; 1986 Oct; 75(10):955-8. PubMed ID: 3795026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharmaceutic and pharmacokinetic aspects of vincamine HCl.
    Ritschel WA; Agrawala P
    Methods Find Exp Clin Pharmacol; 1985 Mar; 7(3):129-36. PubMed ID: 4010386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Agents to improve cerebrovascular circulation and cerebral metabolism--brovincamine].
    Maeda T
    Nihon Rinsho; 1985 Feb; 43(2):389-91. PubMed ID: 3889412
    [No Abstract]   [Full Text] [Related]  

  • 17. [Relative bioavailability of a vincamine retard formulation. Pharmacokinetic study in normal subjects (author's transl)].
    Erking W; Lücker PW; Metz G; Specker M; Wetzelsberger K
    Arzneimittelforschung; 1978; 28(12):2332-6. PubMed ID: 582951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects.
    Millart H; Lamiable D; Houin G; Plat M; Choisy H; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):581-6. PubMed ID: 6654533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of transport and metabolism of the alkaloids: vincamine, vinpocetine and eburnamonine.
    Fandy TE; Abdallah I; Khayat M; Colby DA; Hassan HE
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):259-67. PubMed ID: 26666648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [On the pharmacokinetics of vincamine after i.v. and oral application to the dog (author's transl)].
    Laufen H; Juhran W; Fleissig W; Götz R; Scharpf F; Bartsch G
    Arzneimittelforschung; 1977; 27(6a):1255-64. PubMed ID: 20113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.